September 14, 2026

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director and President
(TSE Growth Code: 4592)
Contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
(TEL. +81-3-6264-3481)

Notice Concerning Differences between the Consolidated Earnings Forecast and Actual Results for 2Q of the Fiscal Year Ending January 31, 2027

SanBio Co., Ltd. (the "Company") hereby announces that the actual results during the second quarter of the fiscal year ending January 31, 2027 (February 1, 2026–July 31, 2026) differed from the consolidated earnings forecast for the corresponding period announced on March 17, 2026, as outlined below.

1. Differences between the consolidated earnings forecast and actual results during the second quarter of the fiscal year ending January 31, 2027

(Million yen)

	Operating revenue	Operating income	Ordinary income	Interim net income attributable to owners of parent	Interim net income per share (yen)
Previous forecast (A) (Announced March 17, 2026)	-	(2,906)	(2,908)	(2,909)	(37.28)
Actual results (B)	-	(1,909)	(1,730)	(1,791)	(22.95)
Change (B) – (A)	-	997	1,178	1,118	
Rate of change (%)	-	-	-	-	
(Ref.) FY2026.1 interim results	-	(1,888)	(2,481)	(1,997)	(27.80)

2. Reasons for difference

Operating loss decreased because expenses for the six months ended July 31, 2026 were lower than initially forecast, reflecting, among other factors, changes in the timing of the acceptance of manufacturing-related costs. In addition, following the listing of AKUUGO® on Japan's National Health Insurance drug price list and the commencement of its commercial launch in May 2026, a portion of the manufacturing costs that had been projected as research and development expenses when the earnings forecast was prepared was recorded as inventories (work in process).

Ordinary loss and net loss attributable to owners of the parent were as shown above due to the decrease in operating loss described above, as well as foreign exchange gains resulting from the depreciation of the yen in relation to foreign currency-denominated loans to the Company's consolidated subsidiary and related receivables.

The full-year earnings forecast for the fiscal year ending January 31, 2027, announced on May 13, 2026, remains unchanged. The manufacturing-related costs that had been scheduled to be recorded during the six months ended July 31, 2026 are now expected to be recorded during the second half of the fiscal year.